PepGen

PepGen LT Debt/Equity

Long-Term Debt to Equity Ratio of PepGen (PEPG) as of Nov 19, 2026.

LT Debt/Equity

0.00

Last updated:

Long-Term Debt to Equity Ratio of PepGen is 2025 0.00 . Long-Term Debt to Equity Ratio of PepGen was 2024 0.00 . It decreases by % lower compared to the previous year.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

PepGen Stock analysis

What does PepGen do? PepGen Inc., based in Cambridge, Massachusetts, is a biotechnology company focused on developing oligonucleotide therapies for neuromuscular and neurologic diseases. The company utilizes its enhanced delivery oligonucleotide (EDO) platform, which employs cell-penetrating peptides to enhance therapeutic delivery. Its lead candidates, PGN-EDO51 for Duchenne muscular dystrophy and PGN-EDODM1 for myotonic dystrophy type 1, are part of a pipeline targeting degenerative conditions. Listed on 6 May 2022, PepGen operates with a team of 56 employees. PepGen is one of the most popular companies on Eulerpool.

Frequently Asked Questions about PepGen stock

On Eulerpool you can find the complete historical development of Long-Term Debt to Equity Ratio PepGen since 2006 – with annual values, charts, and detailed analysis.

The LT Debt/Equity ratio measures long-term financial leverage. It shows how much permanent debt capital is used relative to equity financing.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Long-Term Debt to Equity Ratio's PepGen with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — PepGen

All Key Metrics — PepGen